271 related articles for article (PubMed ID: 23766489)
1. Steady-state pharmacokinetics and metabolism of voriconazole in patients.
Geist MJ; Egerer G; Burhenne J; Riedel KD; Weiss J; Mikus G
J Antimicrob Chemother; 2013 Nov; 68(11):2592-9. PubMed ID: 23766489
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.
Pieper S; Kolve H; Gumbinger HG; Goletz G; Würthwein G; Groll AH
J Antimicrob Chemother; 2012 Nov; 67(11):2717-24. PubMed ID: 22796890
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.
Lazarus HM; Blumer JL; Yanovich S; Schlamm H; Romero A
J Clin Pharmacol; 2002 Apr; 42(4):395-402. PubMed ID: 11936564
[TBL] [Abstract][Full Text] [Related]
5. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects.
Liu P; Foster G; Gandelman K; LaBadie RR; Allison MJ; Gutierrez MJ; Sharma A
Antimicrob Agents Chemother; 2007 Oct; 51(10):3617-26. PubMed ID: 17646413
[TBL] [Abstract][Full Text] [Related]
6. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D
Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
[TBL] [Abstract][Full Text] [Related]
8. Distribution of voriconazole in seven body fluids of adult horses after repeated oral dosing.
Passler NH; Chan HM; Stewart AJ; Duran SH; Welles EG; Lin HC; Ravis WR
J Vet Pharmacol Ther; 2010 Feb; 33(1):35-41. PubMed ID: 20444023
[TBL] [Abstract][Full Text] [Related]
9. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.
Wood N; Tan K; Purkins L; Layton G; Hamlin J; Kleinermans D; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):56-61. PubMed ID: 14616415
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of voriconazole following intravenous and oral administration and body fluid concentrations of voriconazole following repeated oral administration in horses.
Colitz CM; Latimer FG; Cheng H; Chan KK; Reed SM; Pennick GJ
Am J Vet Res; 2007 Oct; 68(10):1115-21. PubMed ID: 17916020
[TBL] [Abstract][Full Text] [Related]
11. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic profile of voriconazole.
Theuretzbacher U; Ihle F; Derendorf H
Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
[TBL] [Abstract][Full Text] [Related]
14. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
Liu P; Foster G; Labadie R; Somoza E; Sharma A
Antimicrob Agents Chemother; 2007 Jan; 51(1):110-8. PubMed ID: 17074798
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in African grey parrots (Psittacus erithacus timneh).
Flammer K; Nettifee Osborne JA; Webb DJ; Foster LE; Dillard SL; Davis JL
Am J Vet Res; 2008 Jan; 69(1):114-21. PubMed ID: 18167096
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring.
Eiden C; Cociglio M; Hillaire-Buys D; Eymard-Duvernay S; Ceballos P; Fegueux N; Peyrière H
Xenobiotica; 2010 Oct; 40(10):701-6. PubMed ID: 20642349
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in Hispaniolan Amazon parrots (Amazona ventralis).
Sanchez-Migallon Guzman D; Flammer K; Papich MG; Grooters AM; Shaw S; Applegate J; Tully TN
Am J Vet Res; 2010 Apr; 71(4):460-7. PubMed ID: 20367055
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole pharmacokinetics and photosensitivity in children with cystic fibrosis.
Markantonis SL; Katelari A; Pappa E; Doudounakis S
J Cyst Fibros; 2012 May; 11(3):246-52. PubMed ID: 22284963
[TBL] [Abstract][Full Text] [Related]
20. Designing voriconazole treatment for racing pigeons: balancing between hepatic enzyme auto induction and toxicity.
Beernaert LA; Baert K; Marin P; Chiers K; De Backer P; Pasmans F; Martel A
Med Mycol; 2009 May; 47(3):276-85. PubMed ID: 18686166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]